Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 870

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 870
---
 Total liabilities, redeemable convertible preferred stock, and stockholders’ deficit                                                                                                                                                                                                                                                     | ​ | $             |  12,514 | ​ | $            |  27,001 |

The accompanying notes are an integral part of these unaudited condensed financial statements.

F-115

TVARDI THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share amounts) (Unaudited)

| ​                                                                         
 ​                                                                         
 ​                                                                         
 ​                                                                         
 Operating expenses:                                                       | ​ 
 ​ | ​                         
 For the Nine Months Ended 
 September 30,             
 2024                      
 ​                         |          ​ | ​ | ​    
 2023 
 ​    |          ​ |
|:--------------------------------------------------------------------------|:--|:--------------------------|-----------:|:--|:-----|-----------:|
| Research and development                                                  | ​ | $                         |     15,047 | ​ | $    |     11,884 |
| General and administrative                                                | ​ |                           |      2,258 | ​ |      |      2,117 |
| Total operating expenses                                                  | ​ |                           |     17,305 | ​ |      |     14,001 |
| Loss from operations                                                      | ​ |                           |    -17,305 | ​ |      |    -14,001 |
| Interest income                                                           | ​ |                           |        615 | ​ |      |      1,005 |
| Net loss                                                                  | ​ | $                         |    -16,690 | ​ | $    |    -12,996 |
| Net loss per share attributable to common stockholders, basic and diluted | ​ | $                         |      -0.87 | ​ | $    |      -0.68 |
| Weighted-average common shares outstanding, basic and diluted             | ​ |                           | 19,192,595 | ​ |      | 19,134,072 |

The accompanying notes are an integral part of these unaudited condensed financial statements.

F-116

TVARDI THERAPEUTICS, INC. CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT (Amounts in thousands, except share amounts) (Unaudited)

| ​                                 
 ​                                 
 ​                                 
 ​                                 
 ​                                 | ​ 
 ​ 
 ​ 
 ​ |                      ​ 
                      ​ 
 Redeem